RARE · Ultragenyx Pharmaceutical
AI read · Neutral
The AI's read
The two new treatments give Ultragenyx products to sell, and the company says its existing products have grown about 20% per year. But GTX-102 failed its Phase 3 study, and Ultragenyx ended UX701 after patient response fell short. Cost cuts are meant to bring spending in line with sales and support a goal of making a profit in 2027. The gains and setbacks point in different directions.